Health Reform Clouds Gerresheimer's Outlook as Goldman and Active Ownership Double Down
12.06.2026 - 14:04:57 | boerse-global.de
The Düsseldorf-based pharmaceutical packaging specialist is caught in a tug-of-war between Berlin and Bay Street. Federal Health Minister Nina Warken brought her sweeping cost-containment package before the Bundestag on Friday, targeting €16.3 billion in savings for statutory health insurers by 2027. Any squeeze on drug pricing and reimbursement ripples straight through to suppliers like Gerresheimer, which sits deep in the pharma value chain. The market has already priced in that pain: the stock has shed roughly 46% over the past twelve months, trading at around €25.50, miles from its former high above €50.
Yet at the same time, two institutional investors are placing aggressive bets on a recovery. Active Ownership disclosed a stake of more than 10% in May, and Goldman Sachs followed suit in June. These heavyweights are looking past the current fog of regulatory and accounting uncertainty, betting that Gerresheimer's core franchise in specialised drug delivery and packaging remains intact.
The political headwind is real, but so is the company's operational response. In Peachtree City, Georgia, Gerresheimer has just commissioned two fully automated pallet storage systems, each 13 metres high and capable of holding 1,104 pallets. The site manufactures inhalers, autoinjectors, infusion components and microbiological test cards. It is part of a $180 million expansion launched in 2024 that added two new buildings totalling 17,900 square metres, predominantly clean room space, and created over 400 jobs. The warehouse management system tracks more than 30 part numbers in real time, enabling full traceability — a regulatory must in medical devices. The company replicated the system at a second facility near Atlanta's airport.
On the financing side, Gerresheimer has won crucial breathing room. Holders of €870 million in Schuldschein loans voted by 96% to extend the deadline for presenting audited financial statements until 30 September 2026, with key debt covenants suspended in the meantime. That gives management time to resolve the audit logjam that has paralysed investor confidence. The company still owes the market a verified annual report; it expects to deliver one within the month.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The accounting crisis has triggered legal fallout on two fronts. The DSW shareholder protection group has commissioned an expert opinion on the liability of former CEO Dietmar Siemssen and former CFO Bernd Metzner, centred on goodwill valuation issues totalling €676 million. DSW managing director Marc Tüngler has warned that a litigation financier could step in once claims become more concrete. Separately, the audit oversight authority APAS has opened a professional disciplinary case against KPMG, alleging the auditors issued an unqualified opinion on the 2024 accounts despite systematic IFRS violations.
Parallel to these legal pressures, Gerresheimer is pushing ahead with the sale of its US subsidiary Centor. Morgan Stanley is running the process. Centor was carried at €292 million on the books at end-2024, and a double-digit number of interested parties have already emerged. Proceeds could help strengthen the balance sheet and fund ongoing investments.
Management has laid out 2026 targets of €2.3-2.4 billion in revenue, an adjusted EBITDA margin of 18-19%, and moderately positive free cash flow — all conditional on a favourable outcome from the ongoing BaFin probe. Once the audited statements land, investors will get their first reliable snapshot of the company's financial health since the crisis erupted.
Gerresheimer at a turning point? This analysis reveals what investors need to know now.
Chart-wise, the stock is hovering just below its 200-day moving average of €25.73, while the 50-day line at €23.97 offers nearby support. Volatility remains elevated, reflecting the mix of political, regulatory and accounting unknowns. For now, Gerresheimer is a high-stakes play where the line between a turn-around opportunity and a value trap is drawn by the thinnest of margins.
Ad
Gerresheimer Stock: New Analysis - 12 June
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
